Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0DLTMU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2017059289A1 ADC-105
|
|||||
| Synonyms |
Thio Hu Anti-CD22 10F4v3 LC K149C-51
Click to Show/Hide
|
|||||
| Organization |
Genentech, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Diffuse large B-cell lymphoma [ICD11:2A81]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Thio hu Anti-CD22 10F4v3 LC K149C
|
Antibody Info | ||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
WO2017059289A1_ADC-105 linker
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Obtained from the Model Organism Data
| Standard Type | Value | Units | Animal Model (No. of PDX) |
|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 34.22
|
%
|
Breast cancer model MMTV-HER2 Fo5
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 16.12% (Day 25) | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (10 mg/kg) via the tail vein on Day 0.
Click to Show/Hide
|
||||
| In Vivo Model | KPL-4 CDX model | ||||
| In Vitro Model | Breast inflammatory carcinoma | KPL-4 cells | CVCL_5310 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 40.75% (Day 11) | Moderate CD22 expression (CD22++) | ||
| Method Description |
Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2 mg/kg) via the tail vein on Day 0.
Click to Show/Hide
|
||||
| In Vivo Model | BJAB CDX model | ||||
| In Vitro Model | Burkitt lymphoma | BJAB cells | CVCL_5711 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 52.27% (Day 11) | Moderate CD22 expression (CD22++) | ||
| Method Description |
Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (4 mg/kg) via the tail vein on Day 0.
Click to Show/Hide
|
||||
| In Vivo Model | BJAB CDX model | ||||
| In Vitro Model | Burkitt lymphoma | BJAB cells | CVCL_5711 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 53.28% (Day 12) | Positive CD22 expression (CD22+++/++) | ||
| Method Description |
Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (5 mg/kg) via the tail vein on Day 0.
Click to Show/Hide
|
||||
| In Vivo Model | WSU-DLCL2 CDX model | ||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 61.34% (Day 11) | Moderate CD22 expression (CD22++) | ||
| Method Description |
Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.
Click to Show/Hide
|
||||
| In Vivo Model | BJAB CDX model | ||||
| In Vitro Model | Burkitt lymphoma | BJAB cells | CVCL_5711 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 81.59% (Day 11) | Moderate CD22 expression (CD22++) | ||
| Method Description |
Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (8 mg/kg) via the tail vein on Day 0.
Click to Show/Hide
|
||||
| In Vivo Model | BJAB CDX model | ||||
| In Vitro Model | Burkitt lymphoma | BJAB cells | CVCL_5711 | ||
Obtained from the Model Organism Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 34.22% (Day 10) | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 15 mg/kg ADC dosing on day 0.
|
||||
| In Vivo Model | Breast cancer model MMTV-HER2 Fo5 | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.